Logo image of ABP

ABPRO HOLDINGS INC (ABP) Stock Fundamental Analysis

NASDAQ:ABP - Nasdaq - US0008471031 - Common Stock - Currency: USD

0.2549  -0.02 (-6.29%)

After market: 0.2471 -0.01 (-3.06%)

Fundamental Rating

0

Overall ABP gets a fundamental rating of 0 out of 10. We evaluated ABP against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of ABP have multiple concerns. ABP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ABP has reported negative net income.
In the past year ABP has reported a negative cash flow from operations.
ABP Yearly Net Income VS EBIT VS OCF VS FCFABP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -2M -4M -6M -8M -10M

1.2 Ratios

ABP's Return On Assets of -259.69% is on the low side compared to the rest of the industry. ABP is outperformed by 93.05% of its industry peers.
Industry RankSector Rank
ROA -259.69%
ROE N/A
ROIC N/A
ROA(3y)-116.21%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABP Yearly ROA, ROE, ROICABP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

ABP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABP Yearly Profit, Operating, Gross MarginsABP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

ABP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABP has been increased compared to 1 year ago.
Compared to 1 year ago, ABP has a worse debt to assets ratio.
ABP Yearly Shares OutstandingABP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M 50M
ABP Yearly Total Debt VS Total AssetsABP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100M 200M 300M

2.2 Solvency

ABP has an Altman-Z score of -61.23. This is a bad value and indicates that ABP is not financially healthy and even has some risk of bankruptcy.
ABP's Altman-Z score of -61.23 is on the low side compared to the rest of the industry. ABP is outperformed by 94.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -61.23
ROIC/WACCN/A
WACC9.6%
ABP Yearly LT Debt VS Equity VS FCFABP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M 200M

2.3 Liquidity

ABP has a Current Ratio of 0.16. This is a bad value and indicates that ABP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ABP (0.16) is worse than 96.97% of its industry peers.
ABP has a Quick Ratio of 0.16. This is a bad value and indicates that ABP is not financially healthy enough and could expect problems in meeting its short term obligations.
ABP's Quick ratio of 0.16 is on the low side compared to the rest of the industry. ABP is outperformed by 96.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.16
ABP Yearly Current Assets VS Current LiabilitesABP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ABP have decreased strongly by -292.67% in the last year.
EPS 1Y (TTM)-292.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-909.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -6.95% on average over the next years.
Based on estimates for the next years, ABP will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y30.22%
EPS Next 2Y14.12%
EPS Next 3Y4.09%
EPS Next 5Y-6.95%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

ABP Yearly Revenue VS EstimatesABP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 20K 40K 60K 80K 100K
ABP Yearly EPS VS EstimatesABP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABP Price Earnings VS Forward Price EarningsABP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABP Per share dataABP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.12%
EPS Next 3Y4.09%

More info and screens

0

5. Dividend

5.1 Amount

ABP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABPRO HOLDINGS INC

NASDAQ:ABP (5/20/2025, 8:00:00 PM)

After market: 0.2471 -0.01 (-3.06%)

0.2549

-0.02 (-6.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners7.1%
Inst Owner Change9.2%
Ins Owners3.06%
Ins Owner Change0.15%
Market Cap13.19M
Analysts80
Price Target2.04 (700.31%)
Short Float %N/A
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS-0.24
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -259.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.21%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.16
Altman-Z -61.23
F-Score2
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-292.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-909.76%
EPS Next Y30.22%
EPS Next 2Y14.12%
EPS Next 3Y4.09%
EPS Next 5Y-6.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y-549%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-531.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-527.29%
OCF growth 3YN/A
OCF growth 5YN/A